-+ 0.00%
-+ 0.00%
-+ 0.00%

Novo Nordisk (CPSE:NOVO B) Reports Phase 3 Win In Obesity Trial For Children Under 12

Simply Wall St·11/17/2026 16:13:31
Listen to the news
  • Novo Nordisk (CPSE:NOVO B) reported phase 3 data showing Wegovy cut BMI meaningfully in children aged 6 to under 12.
  • The trial found no major safety concerns in this younger group, addressing a treatment gap in paediatric obesity care.
  • Positive obesity results in children aged 6 to under 12 could influence Wegovy’s future label and Novo Nordisk’s growth profile. We have also flagged 2 warning signs (1 major) for Novo Nordisk.

For a broader view on how weight management drugs intersect with digital tools and data science, consider the wider set of healthcare names linked to 123 healthcare AI stocks.

CPSE:NOVO B Earnings & Revenue Growth as at Nov 2026
CPSE:NOVO B Earnings & Revenue Growth as at Nov 2026

Novo Nordisk is a large pharmaceuticals group with a DKK1.3 trillion market cap that focuses on researching, manufacturing and distributing treatments for chronic diseases, including obesity. This paediatric obesity trial fits directly into its broader push to expand weight management therapies across different patient groups.

3 things going right for Novo Nordisk that this headline doesn't cover.

How could this Wegovy trial in younger children affect Novo Nordisk’s market opportunity?

A positive phase 3 result in 6 to under 12 year olds points to an extra segment within obesity care that currently has limited pharmacological options. If regulators extend Wegovy’s label below 12, Novo Nordisk would be addressing obesity across more age brackets, which broadens the potential user base for its GLP 1 platform.

Does this Wegovy update change the Novo Nordisk Narrative investors have been using?

The Narrative already leans on Novo Nordisk expanding its GLP 1 and cardiometabolic franchises while trying to keep margins broadly stable under pricing pressure. Strong data in younger children supports the catalyst side of that story because it adds another possible use case for Wegovy alongside ongoing work in oral GLP 1s and new blood and endocrine products.

See how these catalysts shape Novo Nordisk's path to a DKK298 fair value.

What should investors watch next to judge whether this Wegovy paediatric story is gaining traction?

The clearest early marker is whether Novo Nordisk files and then secures regulatory approvals to expand Wegovy’s label to 6 to under 12 year olds in major markets such as the US and EU. Tracking the timing and outcome of those filings, plus any guidance on payer coverage for paediatric obesity, will show how commercially meaningful this trial can become.

Add Novo Nordisk to your Watchlist and get alerts as these catalysts play out.